PARP1 and cancer: On the other hand, [18F]rucaparib displays a more favourable in vivo pharmacokinetics, such as relatively fast and high tumour uptake with longer tumour retention, and potentially can serve as a better PARP imaging agent for visualisation of PARP expression levels in cancers.